How did the Pro Medicus (ASX:PME) share price respond last earnings season?

Pro Medicus' FY21 earnings are imminent. While we wait, let's take a look at how its shares reacted to its FY20 results

| More on:
Three healthcare workers look and point at at medical image

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Pro Medicus Limited (ASX: PME) share price has had a brilliant 12 months on the ASX, and all eyes will be on it tomorrow when the company drops its results for financial year 2021 (FY21).

Since this time last year, the Pro Medicus share price has gained a whopping 136%. For comparison, the S&P/ASX 200 Index (ASX: XJO) increased 24% in the same time frame. However, Pro Medicus shares have dipped by 0.12% in early trade today.

Market watchers will likely be particularly curious about Pro Medicus' earnings since the company's stock hit its highest closing price of all time just over a month ago.

So, as the market awaits the healthcare imaging company's FY21 earnings, lets cast our minds back to its FY20 results and how the Pro Medicus share price reacted.

How did Pro Medicus perform in FY20?

The market wasn't excited about Pro Medicus' FY20 earnings, despite the company's performance being relatively strong. Here's a sample of Pro Medicus' FY20 results:

  • $56.8 million of revenue from underlying operations, 23.9% more than the prior corresponding period
  • Underlying profit before tax increased 33.4% to $30.24 million, excluding a capital sale from the previous period
  • $23.1 million worth of full-year reported profits, a 20.7% increase
  • $43.4 million worth of cash in the bank and no debt
  • A 6-cent final dividend, bringing its total FY20 dividends to 12 cents per share

Pro Medicus' growth was driven by increases in its transaction revenues in North America and Australia.

However, the company's European revenue dropped, mainly because the company completed a $3 million one-off capital sale to the German government in FY19.

The Pro Medicus share price dipped on the back of its FY20 results. It ended the day 2.5% lower than where it started.

What's driven the Pro Medicus share price since?

Pro Medicus has been performing brilliantly on the ASX since it dropped its FY20 earnings.

It has announced a seven-year contract and research agreement with NYU Langone Health, a $10 million deal with LMU Klinikum, a five-year contract with MedStar Health, and a seven-year contract with Intermountain Healthcare.

Additionally, Pro Medicus announced a new on-market share buyback in April. The buyback will see it pocketing 10% of its issued securities.

With so much productivity evidenced in the company's market releases during FY21, investors may be on the edge of their seat waiting to see how the Pro Medicus share price responds to its imminent results.

At its current share price, Pro Medicus has a market capitalisation of around $5.92 billion. It has approximately 104 million shares outstanding.

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned.

The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and has recommended Pro Medicus Ltd. The Motley Fool Australia owns shares of and has recommended Pro Medicus Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

Guess which ASX healthcare stock is jumping 7% on US FDA approval news

This share is giving its shareholders an early Christmas present.

Read more »

A senior pharmacist talks to a customer at the counter in a shop
Healthcare Shares

Is it too late to buy Sigma shares to cash in on the Chemist Warehouse deal?

Can investors still make healthy returns with this stock?

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Why the Mesoblast share price is diving 18% after an FDA win

Investors are sending the Mesoblast share price tumbling on Friday. But why?

Read more »

A happy doctor in a white coat dancing due to his excitement over the EBOS acquisition
Healthcare Shares

Mesoblast share price rockets 30% on big US FDA news

Big news is giving this biotech a huge lift on Thursday.

Read more »

Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.
Healthcare Shares

Guess which ASX healthcare stock is jumping 12% on Wednesday

This shares is rocketing this morning. But why? Let's find out.

Read more »

Man holding out Australian dollar notes, symbolising dividends.
Healthcare Shares

Here is the dividend forecast to 2029 for CSL shares

Can this blue-chip giant provide healthy dividend income?

Read more »

a doctor in a white coat makes a heart shape with his hands and holds it over his chest where his heart is placed.
Healthcare Shares

The best ASX 200 healthcare stocks to buy in 2025

These shares could give your portfolio a healthy boost next year according to Bell Potter.

Read more »

In the lab at work, the mature adult woman and young adult man smile as they review the results of their successful experimentation.
Healthcare Shares

ASX 300 healthcare stock lifts off on promising new results

Up 28% in a year, the ASX healthcare stock is leaping higher on Thursday.

Read more »